The economic burden of cancer in the UK: a study of survivors treated with curative intent. Issue 1 (18th June 2015)

• Record Type: Journal Article
• Authors: Marti, Joachim; Hall, Peter S.; Hamilton, Patrick; Hulme, Claire T.; Jones, Helen; Velikova, Galina; Ashley, Laura; Wright, Penny
• Is Part Of: Psycho-oncology. Volume 25:Issue 1(2016)
• Page Start: 77
• Page End: 83
• Publication Date: 2015-06-18
• Subjects: Cancer -- Psychological aspects -- Periodicals; Cancer -- Social aspects -- Periodicals; Neoplasms -- psychology -- Periodicals; 616.9940019
• DOI: 10.1002/pon.3877
• Languages: English
• ISSNs: 1057-9249

Abstract

Abstract: Objective: We aim to describe the economic burden of UK cancer survivorship for breast, colorectal and prostate cancer patients treated with curative intent, 1 year post‐diagnosis. Methods: Patient‐level data were collected over a 3‐month period 12–15 months post‐diagnosis to estimate the monthly societal costs incurred by cancer survivors. Self‐reported resource utilisation data were obtained via the electronic Patient‐reported Outcomes from Cancer Survivors system and included community‐based health and social care, medications, travel costs and informal care. Hospital costs were retrieved through data linkage. Multivariate regression analysis was used to examine cost predictors. Results: Overall, 298 patients were included in the analysis, including 136 breast cancer, 83 colorectal cancer and 79 prostate cancer patients. The average monthly societal cost was $US409 (95%CI: $US316–$US502) [mean: £260, 95%CI: £198–£322] and was incurred by 92% of patients. This was divided into costs to the National Health Service (mean: $US279, 95%CI: $US207–$US351) [mean: £177, 95%CI: £131–£224], patients' out‐of‐pocket (OOP) expenses (mean: $US40, 95%CI: $US15–$US65) [mean: £25, 95%CI: £9–£42] and the cost of informal care (mean: $US110, 95%CI: $US57–$US162) [mean: £70, 95%CI: £38–£102]. The distribution of costs was skewed with a small number of patients incurring very high costs. Multivariate analyses showed higher societal costs for breast cancer patients. Significant predictors of OOP costs included age and socioeconomic deprivation. Conclusions: This study found the economic burden of cancer survivorship is unevenly distributed in the population and that cancer survivors may still incur substantial costs over 1 year post‐diagnosis. In addition, this study illustrates the feasibility of using an innovative online data collection platform to collect patient‐reported resource utilisation information. Copyright © 2015 John Wiley & Sons, Ltd.